Marco R.
- Country
- Italy
- Department
- SC Oncoematologia Pediatrica
Research Overview
- International Pediatric Study of Arsenic Trioxide and Tretinoin ± Gemtuzumab Ozogamicin for Acute Promyelocytic Leukemia in Children and Adolescents
- International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents
- Phase 3 Study of Imatinib with Cytotoxic Chemotherapy in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Data & Insights
Has run more than one trial at 226 of 363 partner sites.
Specializations
Leukemia Research
This investigator specializes in treating various forms of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), with particular focus on pediatric populations.
- High-risk ALL treatment protocols
- Philadelphia chromosome-positive ALL management
- Down syndrome-associated myeloid leukemia
- Relapsed ALL interventions
Their work encompasses novel therapeutic approaches including targeted immunotherapies and specialized chemotherapy protocols.
Solid Tumors
The investigator conducts research in aggressive pediatric solid tumors, focusing on rhabdomyosarcoma, neuroblastoma, and osteosarcoma.
- High-risk neuroblastoma treatment strategies
- Metastatic osteosarcoma management
- Rhabdomyosarcoma therapy optimization
Their research includes investigation of combination therapies and radiotherapy protocols for improved outcomes.
Rare Diseases
The investigator has expertise in treating Langerhans Cell Histiocytosis (LCH) and other rare pediatric conditions.
- Multi-system LCH treatment protocols
- Early intervention strategies
- Long-term sequelae prevention
Their work includes developing treatment protocols for both single-system and multi-system disease manifestations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.